The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. “This approval in the EU is a landmark moment that begins a new era of precision medicine in prostate cancer,” Johann de Bono, PhD, a professor at The…
You must be logged in to read/download the full post.
The post European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations appeared first on BioNewsFeeds.